Abstract:Background: The role of vitamin D in people who are at risk for type 2 diabetes remains unclear. Purpose: To evaluate whether administration of vitamin D decreases risk for diabetes among people with prediabetes. Data sources: PubMed, Embase, and ClinicalTrials.gov from database inception through 9 December 2022. Study selection: Eligible trials that were specifically designed and conducted to test the effects of oral vitamin D versus placebo on new-onset diabetes in adults with prediabetes. Data extraction: The primary outcome was time to event for new-onset diabetes. Secondary outcomes were regression to normal glucose regulation and adverse events. Prespecified analyses (both unadjusted and adjusted for key baseline variables) were conducted according to the intention-to-treat principle. Data synthesis: Three randomized trials were included, which tested cholecalciferol, 20 000 IU (500 mcg) weekly; cholecalciferol, 4000 IU (100 mcg) daily; or eldecalcitol, 0.75 mcg daily, versus matching placebos. Trials were at low risk of bias. Vitamin D reduced risk for diabetes by 15% (hazard ratio, 0.85 [95% CI, 0.75 to 0.96]) in adjusted analyses, with a 3-year absolute risk reduction of 3.3% (CI, 0.6% to 6.0%). The effect of vitamin D did not differ in prespecified subgroups. Among participants assigned to the vitamin D group who maintained an intratrial mean serum 25-hydroxyvitamin D level of at least 125 nmol/L (≥50 ng/mL) compared with 50 to 74 nmol/L (20 to 29 ng/mL) during follow-up, cholecalciferol reduced risk for diabetes by 76% (hazard ratio, 0.24 [CI, 0.16 to 0.36]), with a 3-year absolute risk reduction of 18.1% (CI, 11.7% to 24.6%). Vitamin D increased the likelihood of regression to normal glucose regulation by 30% (rate ratio, 1.30 [CI, 1.16 to 1.46]). There was no evidence of difference in the rate ratios for adverse events (kidney stones: 1.17 [CI, 0.69 to 1.99]; hypercalcemia: 2.34 [CI, 0.83 to 6.66]; hypercalciuria: 1.65 [CI, 0.83 to 3.28]; death: 0.85 [CI, 0.31 to 2.36]). Limitations: Studies of people with prediabetes do not apply to the general population. Trials may not have been powered for safety outcomes. Conclusion: In adults with prediabetes, vitamin D was effective in decreasing risk for diabetes. Primary funding source: None. (PROSPERO: CRD42020163522).

Schutz vor Typ-2-Diabetes: Gewichtsabnahme plus Remission von Prädiabetes

Kommentar zu "Adipositas/Typ-2-Diabetes: GLP-1 Agonist Tirzepatid fördert Gewichtsabnahme"

Superdrink gegen Typ-2-Diabetes?

Prediabetes remission for type 2 diabetes mellitus prevention

Diet and exercise in the prevention and treatment of type 2 diabetes mellitus

Neue Paradigmen in der Klassifikation und Behandlung des Typ-2-Diabetes

Entstehung und Prävention von Typ-1-Diabetes: die entscheidende Bedeutung der ersten Lebensjahre

Frühes Zeitfenster für Kohlenhydrataufnahme besser als Mittelmeerdiät?

Behaviour change, weight loss and remission of Type 2 diabetes: a community‐based prospective cohort study

Kommentar zu Typ-1-Diabetes: β-Zell-Restfunktion korreliert mit besserer Glukosekontrolle

Besserer Glucosestoffwechsel bei zirkadian synchronisiertem Lebensstil

Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials

Insulinhypersekretion verändert Lipidstoffwechsel und Adipozytenmorphologie

Dietary Interventions for the Prevention of Type 2 Diabetes in High-Risk Groups: Current State of Evidence and Future Research Needs

Blutdrucksenkende Effekte beeinflussen Schutzfunktion neuer Antidiabetika

Typ-1-Diabetes: SGLT2-Hemmung optimiert renalen Energiestoffwechsel

[Prevention of type 2 diabetes and its complications]

Dietary Recommendations for Persons with Type 2 Diabetes Mellitus

Globale Prävalenz von Typ-2-Diabetes und NAFLD

Anti-diabetic agents for prevention of type 2 diabetes mellitus in people with pre-diabetes: a systematic review and network meta-analysis protocol

Different Effects of Lifestyle Intervention in High- and Low-Risk Prediabetes: Results of the Randomized Controlled Prediabetes Lifestyle Intervention Study (PLIS)